Sanofi's corporate venturing unit was among the new investors in a round that will support the advancement of Selecta's gout treatment through Phase 1 trials.

The Novo-backed biotechnology company has filed for an $86.3m initial public offering, after raising $89m in funding since 2005.

Janssen has teamed up with Johnson & Johnson, University of Toronto, Government of Ontario and MaRS Discovery District to bring the JLabs incubator to Canada.

Yabao and South Australia University sign collaboration agreement to identify treatments for cancer.

Lundbeck, Baxter and La Caixa have contributed to a series C round that will support clinical trials for Sanifit's treatments for dialysis patients.

Sanofi's corporate venturing unit was among the new investors in a round that will support the advancement of Selecta's gout treatment through Phase 1 trials.

Roche. which led AveXis' series C round, returned to participate in a series D that will support a clinical trial for its spinal muscular atrophy treatment.